Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables (2021 - 2025)

Autolus Therapeutics (AUTL) has disclosed Receivables for 5 consecutive years, with $33.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 5508.7% year-over-year to $33.5 million, compared with a TTM value of $33.5 million through Sep 2025, up 5508.7%, and an annual FY2024 reading of $1.4 million, up 129.76% over the prior year.
  • Receivables was $33.5 million for Q3 2025 at Autolus Therapeutics, up from $27.3 million in the prior quarter.
  • Across five years, Receivables topped out at $33.5 million in Q3 2025 and bottomed at $123000.0 in Q4 2022.
  • Average Receivables over 5 years is $7.5 million, with a median of $957000.0 recorded in 2024.
  • The sharpest move saw Receivables plummeted 76.29% in 2024, then soared 5508.7% in 2025.
  • Year by year, Receivables stood at $384000.0 in 2021, then tumbled by 67.97% to $123000.0 in 2022, then surged by 408.13% to $625000.0 in 2023, then skyrocketed by 129.76% to $1.4 million in 2024, then surged by 2235.65% to $33.5 million in 2025.
  • Business Quant data shows Receivables for AUTL at $33.5 million in Q3 2025, $27.3 million in Q2 2025, and $14.7 million in Q1 2025.